Sensei Biotherapeutics (NASDAQ:SNSE) Earns Buy Rating from HC Wainwright

Sensei Biotherapeutics (NASDAQ:SNSE)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $4.00 price objective on the stock.

Sensei Biotherapeutics Trading Up 2.5 %

Shares of NASDAQ SNSE opened at $0.53 on Wednesday. The stock has a market capitalization of $13.33 million, a PE ratio of -0.45 and a beta of 0.17. Sensei Biotherapeutics has a twelve month low of $0.38 and a twelve month high of $1.94. The stock has a fifty day simple moving average of $0.50 and a 200-day simple moving average of $0.56.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. National Bank of Canada FI raised its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 45,575 shares of the company’s stock after buying an additional 35,575 shares during the period. National Bank of Canada FI owned approximately 0.18% of Sensei Biotherapeutics worth $27,000 as of its most recent SEC filing. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.